Target intelligence / Profile preview

Ubiquitin-specific peptidase 13 (USP13)

Target
USP13
Molecular classification
Enzyme, Deubiquitinase, Ubiquitin-specific protease family
01

Overview

Ubiquitin-specific peptidase 13 is a member of the ubiquitin-specific protease (USP) family, playing a pivotal role in the deubiquitination process—a form of post-translational modification that influences protein stability, function, and location. USP13 possesses a zinc finger (ZnF) domain, a catalytic USP domain, and two ubiquitin-associated (UBA) domains, allowing it to recognize and remove K48- and K63-linked polyubiquitin chains from key substrates such as PTEN, cyclin D1, Beclin-1, and others. Through this activity, USP13 regulates diverse processes: it stabilizes proteins (preventing degradation), controls cell cycle progression, facilitates DNA damage response, supports energy metabolism, and modulates autophagy. Its dysregulation contributes to various pathological states including cancer, fibrosis, and neurodegenerative diseases, making it a significant target for therapeutic intervention.

Other names
Ubiquitin-specific protease 13USP13
02

Mechanism of action

Inhibition of USP13 increases ubiquitination and proteasomal degradation of its substrates (e.g., cyclin D1, PTEN, Beclin-1). Inhibition can block cell proliferation, induce cell cycle arrest, or alter autophagic flux, depending on substrate and tissue context.

03

Biological functions

Protein degradation (prevents proteasomal degradation by removing ubiquitin from substrates)DNA damage repairCell cycle regulationAutophagyEnergy metabolismER quality controlCell proliferationSignal transduction
04

Disease associations

Cancer (role varies by context; can act as an oncogene or tumor suppressor in specific types)Neurodegenerative diseaseInflammationInfectionIdiopathic pulmonary fibrosis
05

Safety considerations

Broad substrate specificity (possible off-target effects)Context-dependent consequences (oncogene vs. tumor suppressor function)Potential disruption of essential physiological processes (e.g., cell cycle, DNA repair, metabolism)
06

Interacting drugs

Several small molecule inhibitors of USP13 have been described in preclinical literature, but no widely approved drugs directly targeting USP13 are listed in public databases as of the current date

1 more in the full profile.

07

Biomarkers

USP13 expression levelSubstrate (e.g., cyclin D1, PTEN) abundance

Beyond the preview

Go deeper on Ubiquitin-specific peptidase 13 (USP13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-specific peptidase 13 (USP13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call